Shares in GlaxoSmithKline fell 0.4% as the British pharmaceutical giant came under fire for allegedly misleading its shareholders about safety concerns facing its diabetes drug Avandia.

Kaplan Fox & Kilsheimer filed a class-action suit in the U.S. District Court for the Southern District of New York against GSK, the law firm said in a statement Tuesday.